Innovent Biologics

China-based biopharma. Mazdutide (dual GCG/GLP-1) approved by China NMPA June 2025 for chronic weight management; first dual GCG/GLP-1 agonist globally. Partnership with Eli Lilly.

$1801.HKSuzhou, China5,000Biotechnologyinnoventbio.com

SectorsGLP-1

SEC Filings & Documents

Browse all official SEC filings including annual reports, quarterly updates, and material event disclosures.

No Filings Available

SEC filings for this company are not available at the moment.

Innovent Biologics

Compare Innovent Biologics…

China-based biopharma. Mazdutide (dual GCG/GLP-1) approved by China NMPA June 2025 for chronic weight management; first dual GCG/GLP-1 agonist globally. Partnership with Eli Lilly.

$1801.HKSuzhou, China5,000Biotechnologyinnoventbio.com

SectorsGLP-1

SEC Filings & Documents

Browse all official SEC filings including annual reports, quarterly updates, and material event disclosures.

No Filings Available

SEC filings for this company are not available at the moment.

Ask Sterling

Innovent Biologics

SEC Filings & Documents

No Filings Available

Innovent Biologics

SEC Filings & Documents

No Filings Available